Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY P. et al, (2025), The Lancet Infectious Diseases
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY PW. et al, (2025), The Lancet Infectious Diseases
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2025), EClinicalMedicine, 81
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
The prevention and management of chronic kidney disease among patients with metabolic syndrome.
Zhu D. et al, (2025), Kidney Int
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
Nangaku M. et al, (2024), Clin Exp Nephrol, 28, 588 - 595
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Zhu D. et al, (2024), Am J Kidney Dis, 83, 427 - 428
Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.
Wijesurendra RS. et al, (2024), Eur Heart J, 45, 629 - 631
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ. et al, (2024), J Am Soc Nephrol, 35, 202 - 215